『Joint Action』のカバーアート

Joint Action

Joint Action

著者： David Hunter PhD FRACP (Rheum)
無料で聴く

概要

Joint Action is a podcast hosted by David Hunter.



As a consequence of isolation, those living with osteoarthritis related disability may become less fit, more depressed and anxious, more socially isolated and gain weight. It is critical at times like this that people with osteoarthritis have their burden and disability minimised and their knowledge of how to manage the disease enhanced. Join David as he interviews the world's leading experts in osteoarthritis.



Professor David Hunter is a rheumatology clinician researcher whose main research focus has been clinical and translational research in osteoarthritis. He is the Florance and Cope Chair of Rheumatology and Professor of Medicine at University of Sydney and the Royal North Shore Hospital, Sydney, Australia. He is ranked as the worlds leading expert in osteoarthritis on Expertscape.com since 2014.

​


You can send in your questions to hello@jointaction.info and follow David on Instagram at @ProfDavidHunter.


To learn more about our research, visit our website at https://www.osteoarthritisresearch.com.au/


Hosted on Acast. See acast.com/privacy for more information.

Joint Action 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Do you really need surgery for your knee osteoarthritis? with Dr Howard Luks (2021)

    Do you really need surgery for your knee osteoarthritis? with Dr Howard Luks (2021)
    2026/05/10

    The number of surgical procedures for musculoskeletal diseases such as osteoarthritis has increased exponentially over the past years, some of which are unnecessary and leave patients no better off than they were before. Knee replacement surgery can be a wonderful and cost-effective treatment for end-stage osteoarthritis but only when less invasive treatments have failed. There are many factors driving the alarming rates of increased surgery ranging from system-level factors such as inadequate reimbursement for physiotherapy treatment to personal-level factors such as individual beliefs and education of patients and their health care providers. Frequently referrals are made to surgeons as primary care doctors feel there is nothing more they can do. If you are referred it is important to be prepared for what that consultation will involve and to consider whether you truly want/ need surgery.


    On this episode of Joint Action, we are joined by Dr Howard Luks to discuss this topic.


    Dr. Howard Luks is a Board-Certified Orthopaedic Surgeon and Sports Medicine specialist. Howard graduated from New York Medical College and completed his Orthopaedic Surgery residency in 1996 and a fellowship in Sports Medicine at the Hospital for Joint Diseases in NYC in 1997. His focus is on injuries that involve the shoulder, knee, and elbow. He is the Chief of Sports Medicine and Arthroscopy at New York Medical College and Advanced Physician Services.


    CONNECT WITH HOWARD

    • Website: https://www.howardluksmd.com/
    • Podcast: https://www.howardluksmd.com/podcast/the-paul-and-howard-show/


    CONNECT WITH US

    • Naia Health: https://www.naiahealth.com.au/st-leonards-hub
    • Join one of our trials https://www.osteoarthritisresearch.com.au/current-trials
    • Instagram: @ProfDavidHunter
    • Email: hello@jointaction.info
    • Website: www.jointaction.info/podcast


    If you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review!

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    41 分
  • Finding Responders: The Next Phase of OA Biomarkers with Dr Virginia Kraus, Dr Peter Mesenbrink, and Dr Jamie Collins

    Finding Responders: The Next Phase of OA Biomarkers with Dr Virginia Kraus, Dr Peter Mesenbrink, and Dr Jamie Collins
    2026/04/26

    Can identifying the right patients and the right endpoints transform how we test new osteoarthritis treatments? On this week's episode of Joint Action, we unpack what the FNIH Biomarkers Consortium has learned so far, and how their latest phase aims to deliver biomarkers that can make disease-modifying OA drug trials smaller, faster, and more likely to succeed.


    Dr. Virginia Byers Kraus is a Professor of Medicine, Pathology, and Orthopaedic Surgery at Duke University School of Medicine. A rheumatologist and translational scientist, her research focuses on osteoarthritis and biomarker development as part of the international FNIH Biomarkers Consortium.


    Peter G. Mesenbrink, Ph.D., is Executive Director of Biostatistics at Novartis and industry co-chair of the FNIH Biomarkers Consortium. With expertise in adaptive trial design, surrogate endpoint development, and data sharing policy, he is a frequent collaborator across industry, regulatory, and academic communities.


    Dr. Jamie Collins is a biostatistician at Brigham and Women's Hospital and Associate Professor of Orthopaedic Surgery at Harvard Medical School. As lead statistician for the FNIH OA Biomarkers Consortium, her research focuses on strengthening osteoarthritis clinical trials through innovative trial design and prognostic enrichment.


    RESOURCES

    • FNIH: Treatment Response Biomarkers for Disease Modifying Osteoarthritis Drugs (DMOADs)



    CONNECT WITH US

    • Naia Health: https://www.naiahealth.com.au/st-leonards-hub
    • Join one of our trials https://www.osteoarthritisresearch.com.au/current-trials
    • Instagram: @ProfDavidHunter
    • Twitter: @ProfDavidHunter @jointactionorg
    • Email: hello@jointaction.info
    • Website: www.jointaction.info/podcast


    If you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review!

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    29 分
  • Defining the early-stage OA patient: the EsSKOA initiative with Dr Armaghan Mahmoudian

    Defining the early-stage OA patient: the EsSKOA initiative with Dr Armaghan Mahmoudian
    2026/04/12

    What does it actually mean to have 'early-stage' osteoarthritis, and does catching it sooner really make a difference? On this week's episode of Joint Action, learn more about early-stage knee osteoarthritis, how it's defined, and why the EsSKOA initiative is changing the way we identify and understand the condition in its earliest phases.


    Dr. Armaghan Mahmoudian is an Assistant Professor of Movement Sciences and Health at the University of West Florida, where she teaches anatomy and physiology, biomechanics, and research methods, and co-directs the biomechanics and motor learning laboratory. As a clinician-scientist, her research focuses on understanding disease mechanisms and their impact on function and quality of life, with a particular interest in personalised medicine and disease prevention in an ageing population.


    RESOURCES

    • EsSKOA Initiative
    • Journal article Reframing early-stage symptomatic knee osteoarthritis (EsSKOA): A strategic lens for trial design


    CONNECT WITH US

    • Naia Health: https://www.naiahealth.com.au/st-leonards-hub
    • Join one of our trials https://www.osteoarthritisresearch.com.au/current-trials
    • Instagram: @ProfDavidHunter
    • Twitter: @ProfDavidHunter @jointactionorg
    • Email: hello@jointaction.info
    • Website: www.jointaction.info/podcast


    If you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review!

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    39 分
adbl_web_anon_alc_button_suppression_c
まだレビューはありません